Cited by 240Immunotherapy and Immune ResponsesCAR-T cell therapy researchCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

Open access

Wang, Qiong J., Yu, Zhiya, Griffith, Kayla, Hanada, Ken-ichi, Restifo, Nicholas P., Yang, James C.·2016·Cancer Immunology Research

DOI 10.1158/2326-6066.cir-15-0188PMC PMC4775432

Published version of a preprint

Open this paper in CoChat — free account

Abstract

KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. The consistency, frequency, and tumor specificity of these “neoantigens” make them attractive therapeutic targets. Recent data associate T cells that target mutated antigens with clinical immunotherapy responses in patients with metastatic melanoma, lung cancer, or cholangiocarcinoma. Using HLA-peptide prediction algorithms, we noted that HLA-A*11:01 could potentially present mutated KRAS variants. By immunizing HLA-A*11:01 transgenic mice, we generated murine T cells and subsequently isolated T-cell receptors (TCR) highly reactive to the mutated KRAS variants G12V and G12D. Peripheral blood lymphocytes (PBL) transduced with these TCRs could recognize multiple HLA-A*11:01+ tumor lines bearing the appropriate KRAS mutations. In a xenograft model of large established tumor, adoptive transfer of these transduced PBLs reactive with an HLA-A*11:01, G12D-mutated pancreatic cell line could significantly reduce its growth in NSG mice (P = 0.002). The success of adoptive transfer of TCR-engineered T cells against melanoma and other cancers supports clinical trials with these T cells that recognize mutated KRAS in patients with a variety of common cancer types. Cancer Immunol Res; 4(3); 204–14. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-15-0188

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citation
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citation
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,454
Self-citation
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421
Self-citation

Show all 37 references

Sorted by citations

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Self-citation
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 480
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 401
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P. W., Somes, L. K., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 292
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 291
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sánchez, N., Guria, A., Minker, M., Li, G., Fisher, V. A., Sokol, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 253
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
Yossef, R., Tran, E., Deniger, D. C., Gros, A., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Prickett, T. D., Cafri, G., Robbins, P. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122467 · Cited by 213
Targeting public neoantigens for cancer immunotherapy
Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 194
RAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Wang, Z., & Cao, Y. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00176 · Cited by 188
Bispecific antibodies targeting mutant RAS neoantigens
Douglass, J., Hsiue, E. H.-C., Mog, B. J., Hwang, M. S., DiNapoli, S. R., Pearlman, A. H., Miller, M. S., Wright, K. M., Azurmendi, P. A., Wang, Q., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd5515 · Cited by 171
Self-citation
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Bailey, P. J., Chang, D. K.-F., Forget, M., Lucas, F. A. S., Alvarez, H. A., Haymaker, C., Chattopadhyay, C., Kim, S.-H., Ekmekçioglu, S., Grimm, E. A., et al. (2016) · Scientific Reports · doi:10.1038/srep35848 · Cited by 172
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 178
Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients
Cafri, G., Yossef, R., Pasetto, A., Deniger, D. C., Lu, Y., Parkhurst, M. R., Gartner, J. J., Jia, L., Ray, S., Ngo, L. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08304-z · Cited by 165
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 173
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
Mattos‐Arruda, L. D., Vázquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 166
KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
Lal, N., White, B. S., Goussous, G., Pickles, O. J., Mason, M. J., Beggs, A. D., Tanière, P., Willcox, B. E., Guinney, J., & Middleton, G. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1090 · Cited by 158
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
Wagner, S., Mullins, C. S., & Linnebacher, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i48.5418 · Cited by 149
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
Zhang, Z., Rohweder, P. J., Ongpipattanakul, C., Basu, K., Bohn, M.-F., Dugan, E. J., Steri, V., Hann, B., Shokat, K. M., & Craik, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.005 · Cited by 136
Pan-cancer proteogenomics expands the landscape of therapeutic targets
Savage, S. R., Yi, X., Lei, J. T., Wen, B., Zhao, H., Liao, Y., Jaehnig, E. J., Somes, L. K., Shafer, P. W., Lee, T. D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.039 · Cited by 137
Recent insights into the biology of pancreatic cancer
Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 127
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura, S. F., Khan, H. Y., & Azmi, A. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013902 · Cited by 122
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Liu, Q., Li, J., Zheng, H., Yang, S., Hua, Y., Huang, N., Kleeff, J. H., Liao, Q., & Wu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01735-9 · Cited by 133
Recent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 132
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, T. K. H., Skoulidis, F., Kerr, K. M., Ahn, M., Kapp, J. R., Soares, F. A., & Yatabe, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107293 · Cited by 133
Liquid Biopsy, ctDNA Diagnosis through NGS
Chen, L., Liu, X., Zheng, B., Ke, R., & Tzeng, C. (2021) · Life · doi:10.3390/life11090890 · Cited by 117
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Poole, A. J., Karuppiah, V., Hartt, A., Haidar, J. N. S., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C. N., Dias, J. C., Harper, S. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32811-1 · Cited by 115
Neoantigen prediction and the need for validation
Vitiello, A., & Zanetti, M. (2017) · Nature Biotechnology · doi:10.1038/nbt.3932 · Cited by 116
Glycan-directed CAR-T cells
Steentoft, C., Migliorini, D., King-Peoples, T. R., Mandel, U., June, C. H., & Posey, A. D. (2018) · Glycobiology · doi:10.1093/glycob/cwy008 · Cited by 102
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Lu, D., Chen, Y., Jiang, M., Wang, J., Li, Y., Ma, K., Sun, W., Zheng, X., Qi, J., Jin, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42010-1 · Cited by 101
The neoepitope landscape in pediatric cancers
Chang, T., Carter, R. A., Li, Y., Li, Y., Wang, H., Edmonson, M. N., Chen, X. '., Arnold, P. Y., Geiger, T. L., Wu, G., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0468-3 · Cited by 99
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
Rath, J. A., & Arber, C. (2020) · Cells · doi:10.3390/cells9061485 · Cited by 104
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
Parkhurst, M. R., Goff, S. L., Lowery, F. J., Beyer, R. K., Halas, H. K., Robbins, P. F., Prickett, T. D., Gartner, J. J., Sindiri, S., Krishna, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03109-0 · Cited by 93
Self-citation
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 83
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 81
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Nagasaka, M., Potugari, B. R., Nguyen, A., Sukari, A. W., Azmi, A. S., & Ou, S. I. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102309 · Cited by 80
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
Choi, J., Goulding, S. P., Conn, B. P., McGann, C. D., Dietze, J. L., Kohler, J., Lenkala, D., Boudot, A. J., Rothenberg, D., Turcott, P. J., et al. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100084 · Cited by 70
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Pang, Z., Lu, M., Zhang, Y., Gao, Y., Bai, J. J., Gu, J., Xie, L., & Wu, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00534-0 · Cited by 70
Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines
Mehta, N. K., Pradhan, R., Soleimany, A. P., Moynihan, K. D., Rothschilds, A. M., Momin, N., Rakhra, K., Mata-Fink, J., Bhatia, S. N., Wittrup, K. D., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0563-4 · Cited by 68
Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy
Zhang, X., Qi, Y. A., Zhang, Q., & Liu, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109542 · Cited by 65
Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors
Wang, W., Yuan, T., Ma, L., Zhu, Y., Bao, J., Zhao, X., Zhao, Y., Zong, Y., Zhang, Y., Yang, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105810 · Cited by 63
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 62
Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues
Abelin, J. G., Bergstrom, E. J., Rivera, K. D., Taylor, H. B., Klaeger, S., Xu, C., Verzani, E. K., White, C. J., Woldemichael, H. B., Virshup, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37547-0 · Cited by 65
Adoptive Cell Therapy for Metastatic Melanoma
Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000240 · Cited by 62
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“Clinical evaluations of KRAS inhibitors, sotorasib and adagrasib, were conducted as basket trials and included solid tumors with KRAS G12C regardless of the tissue of origin.”
Background
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
Deniger, D. C., Pasetto, A., Tran, E., Parkhurst, M. R., Cohen, C. J., Robbins, P. F., Cooper, L. J. N., & Rosenberg, S. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.51 · Cited by 59
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses
Arbelaez, C. A., Estrada, J., Gessner, M. A., Glaus, C., Morales, A. B., Mohn, D., Phee, H., Lipford, J. R., & Johnston, J. A. (2020) · npj Vaccines · doi:10.1038/s41541-020-00253-9 · Cited by 58
Targeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 57
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 57
Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
Levin, N., Paria, B. C., Vale, N. R., Yossef, R., Lowery, F. J., Parkhurst, M. R., Yu, Z., Florentin, M., Cafri, G., Gartner, J. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0849 · Cited by 54
Self-citation
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Richard, G., Princiotta, M. F., Bridon, D. P., Martin, W. D., Steinberg, G. D., & Groot, A. S. D. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2012456 · Cited by 49
An in silico—in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients
Mishto, M., Mansurkhodzhaev, A., Ge, Y., Bitra, A., Cordfunke, R. A., Henze, S., Paul, D., Sidney, J., Urlaub, H., Neefjes, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02572 · Cited by 48
Shared Neoantigens: Ideal Targets for Off-The-Shelf Cancer Immunotherapy
Zhao, W., Wu, J., Chen, S., & Zhou, Z. M. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0184 · Cited by 49
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 45
Self-citation
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 50
Neoantigen cancer vaccines: a new star on the horizon
Li, X., You, J., Hong, L., Liu, W., Guo, P., & Hao, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0395 · Cited by 53
Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors
Wang, X., Wang, W., Zou, S., Xu, Z., Cao, D., Zhang, S., Wei, M., Zhan, Q., Wen, C., Li, F., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00990-9 · Cited by 46
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Bianchi, V., Harari, A., & Coukos, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01215 · Cited by 47
Current Status of Immunotherapies for Treating Pancreatic Cancer
Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 47
Neoantigens in Hematologic Malignancies
Biernacki, M. A., & Bleakley, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00121 · Cited by 47
Targeting neoantigens for cancer immunotherapy: Table 1.
Lu, Y., & Robbins, P. F. (2016) · International Immunology · doi:10.1093/intimm/dxw026 · Cited by 44
Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 43
T-Cell Transfer Therapy Targeting Mutant KRAS
Maoz, A., Rennert, G., & Gruber, S. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616637 · Cited by 43
Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens
Parikh, A. Y., Masi, R., Gasmi, B., Hanada, K., Parkhurst, M. R., Gartner, J. J., Sindiri, S., Prickett, T. D., Robbins, P. F., Zacharakis, N., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03476-6 · Cited by 44
Self-citation
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 42
Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment
John, S., Antonia, S. J., Rose, T. A., Seifert, R. P., Centeno, B. A., Wagner, A. S., & Creelan, B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0258-x · Cited by 39
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
Hwang, M. S., Miller, M. S., Thirawatananond, P., Douglass, J., Wright, K. M., Hsiue, E. H.-C., Mog, B. J., Aytenfisu, T. Y., Murphy, M. B., Azurmendi, P. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25605-4 · Cited by 38
Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective
Liu, D., Liu, L., Li, X., Wang, S., Wu, G., & Che, X. (2024) · Vaccines · doi:10.3390/vaccines12080950 · Cited by 40
Discovery through clinical sequencing in oncology
Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 38
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
Cinausero, M., Laprovitera, N., Maglio, G. D., Gerratana, L., Riefolo, M., Macerelli, M., Fiorentino, M., Porcellini, E., Buoro, V., Gelsomino, F., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919885540 · Cited by 37
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 37
Update on Targeted Therapy in Medullary Thyroid Cancer
Okafor, C. I., Hogan, J., Raygada, M. J., Thomas, B. J., Akshintala, S., Glod, J. W., & Rivero, J. D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.708949 · Cited by 36
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma
Wei, T., Leisegang, M., Xia, M., Kiyotani, K., Li, F., Zeng, C., Deng, C., Jiang, J., Harada, M., Agrawal, N., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929726 · Cited by 33
Mutant KRAS Peptide Targeted CAR-T Cells Engineered for Cancer Therapy
Benton, A., Liu, J.-G., Poussin, M., Goldgewicht, A. L., Udawela, M., Bear, A. S., Wellhausen, N., Carreno, B. M., Smith, P., Beasley, M. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.006 · Cited by 32
Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer
Zhou, J., Zhao, W., Wu, J., Lu, J., Ding, Y., Wu, S., Wang, H., Ding, D., Mo, F., Zhou, Z. M., et al. (2019) · BioMed Research International · doi:10.1155/2019/8103142 · Cited by 32
Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens
Moradi, A., Pourseif, M. M., Jafari, B., Parvizpour, S., & Omidi, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104790 · Cited by 34
Emerging Therapies in the Management of Advanced-Stage Gastric Cancer
Kumar, V., Soni, P., Garg, M., Kamholz, S. L., & Chandra, A. B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00404 · Cited by 31
Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy
Hinrichs, C. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1294 · Cited by 30
Targeting KRAS in Non-Small Cell Lung Cancer
de la Fuente, E. C., Olmedo, M. E., Rueda, A. G., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 34
Immune vulnerabilities of mutant KRAS in pancreatic cancer
Cheng, N. C., & Vonderheide, R. H. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.004 · Cited by 32
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies
Jones, H. F., Molvi, Z., Klatt, M. G., Dao, T., & Scheinberg, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585385 · Cited by 28
Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities
Lee, M. S., & Pant, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321255 · Cited by 30

Authors: Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C.
Affiliations: National Institutes of Health (US)
Corresponding author: Wang, Qiong J.
Yang, James C.
ORCID: Wang, Qiong J.
Yu, Zhiya
Hanada, Ken-ichi
Restifo, Nicholas P.
Yang, James C.
Venue: Cancer Immunology Research
Publisher: American Association for Cancer Research (AACR)
Published: 2016-02-29
Volume: 4
Issue: 3
Pages: 204-214
ISSN: 2326-6066 (ISSN-L)
2326-6074
DOI: 10.1158/2326-6066.cir-15-0188
PMC: PMC4775432
OpenAlex: W2239878160
Cited by: 240
References: 37
Citations by year: 2026: 17 · 2025: 27 · 2024: 27 · 2023: 30 · 2022: 36 · 2021: 29 · 2020: 24 · 2019: 19 · 2018: 11 · 2017: 13 · 2016: 7
FWCI: 10.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Immunology Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: KRAS mutation, T cell receptor engineering, neoantigens, HLA-A*11:01, pancreatic cancer, adoptive T cell therapy, xenograft tumor growth, cancer immunotherapy
MeSH terms: Amino Acid Sequence, Animals, Humans, Lymph Nodes, Mice, Transgenic, Neoplasm Transplantation, Pancreatic Neoplasms, Receptors, Antigen, T-Cell, Spleen, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Adoptive Transfer, Mutation, Missense, Cell Line, Tumor, HLA-A11 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks